Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T12:05:43.348Z.
Calculation as of: 2026-10-06T12:05:43.348Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
EV/EBIT Ratio
N/A
TTM Avg
59.55x
3Y Avg
59.55x
5Y Avg
78.29x
Market Cap
$1.12B
EV/EBIT Ratio
13.85x
TTM Avg
11.45x
3Y Avg
12.41x
5Y Avg
16.01x
Market Cap
$1.16B
EV/EBIT Ratio
17.49x
TTM Avg
14.99x
3Y Avg
31.51x
5Y Avg
159.52x
Market Cap
$1.20B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.21B
EV/EBIT Ratio
59.25x
TTM Avg
63.01x
3Y Avg
63.01x
5Y Avg
63.01x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A | 59.55x | 59.55x | 78.29x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 13.85x | 11.45x | 12.41x | 16.01x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 17.49x | 14.99x | 31.51x | 159.52x |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.21B | 59.25x | 63.01x | 63.01x | 63.01x |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 2.12x | 2.12x | 2.12x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
